CoronavirusUnlikely vaccine caused volunteer-developed disease, says Oxford

Unlikely vaccine caused volunteer-developed disease, says Oxford

In a document sent to the volunteers, he explains that “there was not enough evidence to say that it is true that the diseases were related or not to the vaccine” against Covid-19

The chances that the disease a volunteer from the University of Oxford and AstraZeneca trials developed is an effect of the Covid-19 vaccine  are slim, reveals a document sent to participants.

The UK trial volunteer developed a “potentially unexplained illness,” AstraZeneca reported.

The American newspaper The New York Times identified it as transverse myelitis, and the trials were suspended for a few days. An independent committee was created to assess the risks of the vaccine. The committee “concluded its investigation” and determined “that the trials could be resumed in the UK as they were safe,” the drugmaker announced on Saturday, without giving further details.

But in a document sent to volunteers, dated September 11, the University of Oxford explains that “in the current trial we have performed safety reviews when volunteers in the ChAdOx1 nCoV-19 trials developed unexplained neurological symptoms, including different sensations. or limb weakness, and we paused the study while the review was carried out.

It adds that “after an independent review, it was considered that either these diseases were unlikely to be associated with the vaccine, or there was insufficient evidence to say for certain that the diseases were or were not vaccine-related. In each of these cases, after considering the information, the independent verifiers recommended that vaccinations continue ”.

The University notes that it will continue to “closely monitor” both affected volunteers and other participants, who are asked to report any unexpected symptoms. “With any new medicine or vaccine there is always the possibility of an unexpected side effect,” he says.

Covid-19 vaccine trials resume

The British pharmaceutical group AstraZeneca and the University of Oxford announced last Saturday that they resumed their clinical trials in the United Kingdom to find a vaccine against the new coronavirus and that “next Monday” they will be resumed in Brazil, one of the four countries in which being tested.

The vaccine developed by AstraZeneca and the British University of Oxford is one of the most advanced Western projects, tested with tens of thousands of volunteers in the United Kingdom, Brazil, South Africa and, as of August 31, in the United States, in which It is called phase 3 of the trials, that is, the last one, in which its safety and efficacy are verified.

The suspension of the trials was decided this week following the appearance of a ‘potentially unexplained illness’, possibly a serious side effect, in a participant in the UK.

That mishap does not invalidate the objective of the experiments: to obtain “a vaccine by the end of the year” or “the beginning of next year,” the pharmaceutical company said.

“Clinical trials of the AstraZeneca coronavirus vaccine were resumed in the UK after the Medicines Health Regulatory Authority (MHRA) confirmed that it was not dangerous,” the pharmaceutical company stated.

Following the volunteer’s unexpected illness, AstraZeneca and Oxford created an independent committee to assess the risks of the vaccine. The committee “concluded their investigation and told the MHRA that the trials could be resumed in the UK as they were safe,” AstraZeneca added.

In a separate statement, Oxford University confirmed the resumption on Saturday, noting that “in large-scale tests like this one, some participants are expected to become ill.”

“Each case must be carefully analyzed to ensure a thorough safety assessment,” the university added.

Florent Malicehttps://www.newsalarms.com/
Malice is an Irish sports journalist and former amateur and part-time road bicycle racer, He wrote for The Sunday Times newspaper and others, and published a number of books.

Latest news

Blockchain IDOs and Presales You Should Know About

There’s never a lack of new projects opportunities when it comes to blockchain and decentralized finance (DeFi). But it...

The 10 rules to prepare for the crypto bear market by the savvy investor

While the Bitcoin and cryptocurrency market reached a record capitalization in November 2021 (nearly $ 3 trillion), the memories left by...

Latin America’s E-commerce Giant Opens Up To Buying Bitcoin

Bitcoin (BTC) and cryptocurrencies are increasingly accepted every day for payments for goods and services . This time, it's the South American...

Binance Welcomes Arbitrum – Ethereum’s Second Layer!

For many months, the Ethereum (ETH) network has faced massive congestion resulting in higher transaction fees . Fortunately, second-layer solutions continue to...

The Bitcoin forever changed by this evolution

As of June 12, 2021, the Bitcoin Network (BTC) has been patiently awaiting the entry into force of its Taproot...

Regulation and taxation on cryptocurrency mining in Russia

The Duma wants to regulate Bitcoin and cryptocurrency mining in the country. The laws would notably make it possible to...

Must read

Blockchain IDOs and Presales You Should Know About

There’s never a lack of new projects opportunities when...

The 10 rules to prepare for the crypto bear market by the savvy investor

While the Bitcoin and cryptocurrency market reached a record capitalization in...

Latin America’s E-commerce Giant Opens Up To Buying Bitcoin

Bitcoin (BTC) and cryptocurrencies are increasingly accepted every day for...

Binance Welcomes Arbitrum – Ethereum’s Second Layer!

For many months, the Ethereum (ETH) network has faced...

The Bitcoin forever changed by this evolution

As of June 12, 2021, the Bitcoin Network (BTC)...

You might also like
Recommended to you